



UNITED STATES PATENT AND TRADEMARK OFFICE

A

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/599,974	02/14/1996	JEFFREY M. FRIEDMAN	600-1-162CP1	1513

7590 01/13/2005

DAVID A JACKSON
KLAUBER AND JACKSON
411 HACKENSACK AVENUE
HACKENSACK, NJ 07601

EXAMINER

O HARA, EILEEN B

ART UNIT	PAPER NUMBER
	1646

DATE MAILED: 01/13/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	08/599,974	FRIEDMAN ET AL.
Examiner	Art Unit	
Eileen O'Hara	1646	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 04 October 2004.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 21, 22, 24, 26-28, 34-48, 51, 52 and 67 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 21, 22, 24, 26-28, 34-48, 51, 52 and 67 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date. _____	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
	6) <input type="checkbox"/> Other: _____

DETAILED ACTION

1. Claims 21, 22, 24, 26-28, 34-48, 51, 52 and 67 are pending in the instant application. Claims 21, 22, 24, 27, 28, 34, and 67 have been amended and claims 1-19, 25, 29-33, 49, 50, 53-66 and 68 have been canceled as requested by Applicant in the Paper filed Oct. 4, 2004.

All claims are currently under examination.

Withdrawn Objections and Rejections

2. Any objection or rejection of record which is not expressly repeated in this action has been overcome by Applicant's response and withdrawn.

New Rejections

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

3. Claims 24, 26, 27, 36, 38, 40, 42, 44, 46, 48 and 52 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 24, 26, 27, 36, 38, 40, 42, 44, 46, 48 and 52 are indefinite because they encompass an isolated DNA molecule encoding a leptin receptor, wherein the DNA molecule is amplifiable with a PCR probe. Defining a nucleic acid that is "amplifiable" under non-specified circumstances does not clearly set forth the metes and bounds of the patent protection desired.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

4. Claims 24, 26, 36, 38, 40, 42, 44, 46, 48 and 52 are rejected under 35 U.S.C. 102(e) as being anticipated by Tartaglia et al., US Patent No. 6,506,877, filing date Dec. 28, 1995.

Claims 24, 26, 36, 38, 40, 42, 44, 46, 48 and 52 encompass an isolated nucleic acid encoding a leptin receptor which is a soluble receptor and which is encoded by a nucleic acid which is amplifiable with a PCR probe selected from a probe for clone seven and a probe for clone 11 or both, nucleic acids that hybridize to a DNA molecule of SEQ ID NO: 9, expression vectors, which may be transgenic, host cells that may be *E. coli*, *Saccharomyces*, *Pichia*, *CHO* cells, and method of preparing polypeptide recombinantly.

Tartaglia et al. discloses a protein (SEQ ID NO: 2) that is 100% identical to amino acids 1-796 of SEQ ID NO: 10 of the instant invention, which is the soluble portion of the protein, and nucleic acid of SEQ ID NO: 1 that encodes the protein. The nucleic acid of Tartaglia et al. is 100% identical to nucleotides 1-2432 of SEQ ID NO: 9 of the instant invention, which encodes amino acids 1-796 of SEQ ID NO: 10. Probes to clones 7 and 11 (SEQ ID NOS: 42-45) are identical to regions of the nucleic acid of Tartaglia et al. (see attached sequence alignments) and therefore the DNA of Tartaglia would be amplifiable with those probes. Tartaglia also teaches expression vectors, which may be transgenic, host cells that may be *E. coli*, *Saccharomyces*, *Pichia*, *CHO* cells, and method of preparing polypeptide recombinantly (column 8, lines 3-5,

column 13, lines 29-50, column 18, line 5 to column 19, line 62. Therefore, Tartaglia et al. anticipates the claims.

Maintained Rejections

Double Patenting

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office Action.

5. Claims 21, 22, 24, 26-28, 34-48, 51, 52 and 67 remain provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 29-31 of copending Application No. 08/783,734. Applicants traverse the rejection and assert that in as much as the pending claims in the instant Application cover nucleic acids coding on expression OB-Re, these are patently distinct from the oligonucleotides hybridizable to OB-Re in claims 29-31 of the copending '734 application. Applicants' arguments have been fully considered but are not deemed persuasive. There are no size limitations for the claimed oligonucleotides of the '734 application, and so they read on the nucleic acids in the instant application. Additionally, even if the sizes of the oligonucleotides were limited in size, it would be *prima facie* obvious to one of ordinary skill in the art to make smaller fragments of the nucleic acid in order to use them as probes in hybridization experiments. Therefore, the rejection is maintained.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

6. Claims 21, 22, 24, 26-27, 34-48, 51, 52 and 67 remain rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Applicants traverse the rejection on pages 6-7 of the response, and assert that Applicants have described and provided the specific DNA and protein sequence for soluble receptor species OB-Re (SEQ ID NO: 10), as well as the truncated variant of amino acids 28-805 of SEQ ID NO: 10, which was isolated as a naturally occurring soluble receptor species, using procedures and methods detailed in the specification. Applicants assert that the skilled artisan could readily, without undue experimentation, isolate additional species of the genus of such soluble receptors, including additional and related allelic variants thereof.

Applicants' arguments have been fully considered but are not deemed persuasive. The issue is not undue experimentation to isolate additional species, but that of written description. An adequate written description of a DNA (or encoded polypeptide), "requires a precise definition, such as by structure, formula, chemical name, or physical properties," not a mere wish or plan for obtaining the claimed chemical invention. Fiers v. Revel, 984 F.2d 1164, 1171, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993). Accordingly, "an adequate written description of a DNA requires more than a mere statement that it is part of the invention and reference to a potential

method for isolating it; what is required is a description of the DNA itself.” Id at 1170, 25 USPQ2d at 1606.”

Therefore, the rejection is maintained.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

7. Claims 24, 36, 38, 40, 42, 44, 46, 48 and 52 remain rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Applicants have amended claim 24 to recite “under moderate stringency conditions”, however, the claim is still indefinite, because the moderate conditions recited on page 39 is exemplary, so that the resulting claim still does not clearly set forth the metes and bounds of the patent protection desired.

Therefore, the rejection is maintained.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

8. Claims 22, 24, 26, 34-48, 51 and 52 remain rejected under 35 U.S.C. 102(e) as being anticipated by Tartaglia et al., US Patent No. 6,506,877, filing date Dec. 28, 1995.

Applicants traverse the rejection on pages 7-8 of the response and assert that Tartaglia et al. does not anticipate the soluble leptin receptor of the instant invention as claimed by Applicants, cite *PPG Industries, Inc. vs Guardian Industries Corp.*, and assert that Tartaglia et al. neither discloses every element of the rejected claims nor enables one skilled in the art to make the anticipating subject matter. Applicants point to column 6 of Tartaglia in which the extracellular domain is from about amino acid residues 23-837, and assert that Tartaglia et al. does not teach, anticipate or even suggest the soluble receptor OB-Re of SEQ ID NO: 10 of the instant invention having an end at amino acid His⁷⁹⁶.

Applicants' arguments have been fully considered but are not deemed persuasive. Because claim 22 is so broadly written and does not require any sequence, Tartaglia et al. anticipates the claims. Claim 22 recites "A isolated leptin receptor (OB-R) polypeptide which is a soluble receptor." There is no recitation of any structure. Tartaglia et al. teaches an isolated leptin receptor (OB-R) polypeptide which is a soluble receptor. The additional, divergent sequences after His⁷⁹⁶ are not relevant to the invention as claimed. Additionally, Tartaglia et al. teach that truncations of specific functional domains can be made. At column 7, lines 61-67, Tartaglia et al. states:

"In particular, the invention described in the subsections below encompasses ObR, polypeptides or peptides corresponding to functional domains of the ObR (e.g., ECD, TM or CD), mutated, truncated or deleted ObRs (e.g. an ObR with one or more functional domains or portions thereof deleted, such as .DELTA.TM and/or .DELTA.CD),"

Therefore, Tartaglia et al. anticipates the claims, and the rejection is maintained.

It is believed that all pertinent arguments have been answered.

Conclusion

9. No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Eileen B. O'Hara, whose telephone number is (571) 272-0878. The examiner can normally be reached on Monday through Friday from 10:00 AM to 6:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached at (571) 272-0961.

The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://portal.uspto.gov/external/portal/pair>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll free).

Eileen B. O'Hara, Ph.D.
Patent Examiner

Eileen B. O'Hara

**EILEEN B. O'HARA
PATENT EXAMINER**